Share

Contacts

  • RaySearch Laboratories
    Sveavägen 44 10365 Stockholm
    +46 8 510 530 00
    +46 8 545 061 39
    http://www.raysearchlabs.com
  • Quotes

    In the fourth quarter of 2023, net sales rose by 13 percent. Revenue from support rose by 40 percent. Operating profit amounted to SEK 44.4 M (20.7) in the fourth quarter and to SEK 114.9 M (42.7) for the full year.
    Johan Löf, CEO of RaySearch
    "We are excited to welcome DrugLog to RaySearch's product portfolio. Since its inception, RaySearch has focused on software for optimizing and planning radiation therapy. However, the long-term vision is to provide software support for all types of cancer treatments, including chemotherapy and surgery. As a first step, we intend to add support for treatment planning in RayStation and workflows in RayCare for chemotherapy management. We anticipate that these extensions will be launched by 2026 at the latest. DrugLog will be an excellent complement to this and significantly improve and simplify quality assurance in cancer treatment with chemotherapy. We look forward to integrating DrugLog into our offering and continuing to deliver innovative solutions to cancer centers worldwide."
    Johan Löf, founder and CEO, RaySearch
    I am a strong believer of the clinical benefits of adaptive radiation therapy. The tools have been available in RayStation for many years and RayCare has from the beginning been developed to facilitate the implementation of OART in clinical routine. In ARTemis we will have a very strong solution to enable online adaptive and I could not have asked for a better partner than The Royal Marsden, with which we have an established and fruitful collaboration, to be the pioneering center for this exciting new solution.
    Johan Löf, founder and CEO, RaySearch
    This is an important milestone for RaySearch. We have invested significant resources in developing the by far most advanced treatment planning system, with support for almost all available treatment machines. Today, we see that our efforts have paid off with over 1,000 centers who have purchased RayStation. I also note with pride that ten of the fifteen highest ranked cancer hospitals in the world, according to a ranking by Newsweek, are current customers of ours. This reflects our strong position also in the top segment and confirms RaySearch as a leading vendor of high-quality cancer treatment.
    Johan Löf, founder and CEO, RaySearch
    The Froedtert & MCW health network is an excellent example of the kind of health system that will enjoy the maximum benefit from RaySearch's technologies. RayStation's support for multiple delivery systems makes implementation easier and more effective at many levels. The medical staff will be able to use a single platform and determine the ideal treatment modality for every cancer patient. We look forward to working with the Froedtert & MCW cancer team for many years to come.
    Johan Löf, founder and CEO, RaySearch
    Further enhancing the capabilities of multi-modality treatments is key for RaySearch in the ambition to provide tools to create the best treatment plans for cancer patients. With RayStation 2024A we also continue with improvements within fast adaptive re-planning, which will be an important focus area during the coming years.
    Johan Löf, founder and CEO, RaySearch
    Online adaptive has been a key focus for RaySearch for many years and I am impressed by the work that is done at Vejle. RayStation has very advanced tools available for taking online adaptive into clinical routine and the work done by Vejle is showcasing what groundbreakning possibilities our users have to further advance cancer treatments.
    Johan Löf, founder and CEO, RaySearch
    We are dedicated to pushing the boundaries of innovation for improved patient care and operational excellence. Our goal with the new workflow is to significantly reduce the time that a patient undergoing short-course palliative radiotherapy has to stay in the hospital.
    Rune S. Thing, medical physicist at Vejle Hospital
    In the third quarter of 2023, net sales rose by 20 percent. Revenue from support rose by 23 percent. Operating profit amounted to SEK 28.6 M (12.0) in the third quarter and to SEK 70.5 M (22.0) for the first nine months.
    Johan Löf, CEO of RaySearch
    I am greatly encouraged that OHSU will integrate RayStation with Radixact, marking another step forward in our commitment to advancing radiation technology. This collaboration broadens the availability of our innovative solutions, ultimately enhancing the quality of care for cancer patients.
    Johan Löf, founder and CEO, RaySearch
    We are happy to add these centers to our growing installed base. The strategy for RaySearch has from the beginning been to support virtually all commercially available machines. Right now, RayStation is the only treatment planning system available that can facilitate a unified workflow for such large and diversified centers as Baptist Health Lexington and Baptist Health Hamburg and we are looking forward to a successful collaboration.
    Johan Löf, founder and CEO, RaySearch
    Mass General is truly a pioneering collaboration partner to RaySearch. They were one of the very first users of RayStation in the world and we have benefitted greatly from various collaboration projects that we have done together during the years. I am happy that they now have the opportunity to start using RayStation also for their proton treatments.
    Johan Löf, founder and CEO, RaySearch
    RaySearch’s expertise in oncology software and Mevion Medical Systems’ latest technological advancements will continue to bring innovation in the proton therapy field and we look forward to working together with Mevion to further advance proton cancer treatments.
    Johan Löf, founder and CEO, RaySearch
    The synergy between Mevion Medical Systems and RaySearch Laboratories continues to redefine the landscape of cancer care. The united strength of our collaborative partnership is accelerating the deployment of emerging proton therapy developments. We are committed to breaking down technological and clinical access barriers to superior proton therapy technology.
    Tina Yu, Ph.D., CEO and President of Mevion Medical Systems
    PSI is an exceptional place to treat cancer, and I am proud to welcome them as customers. It is also very exciting to engage in several research projects together with a partner with such strong research capabilities. This will be beneficial for the next generation of RayStation as well as an important step in fulfilling our vision of a world where cancer is conquered.
    Johan Löf, founder and CEO, RaySearch
    By combining proton therapy with advanced treatment planning system as proposed by RaySearch, we can push the boundaries of optimal cancer care. We look forward to collaborating with one of the leading developers of treatment planning systems to share our expertise in proton therapy and advance research in various areas, including but not limited to treatment plan adaptation.
    Damien C. Weber, Chairman of the proton Therapy Center, Paul Scherrer Institute
    We are proud to work with a company that is ushering in a new era of proton therapy. P-Cure is a pioneer in the development of upright radiation therapy, and the ability to provide a proton system in a regular linac room has great potential to expand proton therapy.
    Johan Löf, founder and CEO, RaySearch
    We are very pleased to provide C.R.O. Aviano with RayStation and RayCare. The adoption of both RaySearch solutions at C.R.O. Aviano will enhance implementation efficiency as well as the possibility to optimize clinical excellence of proton therapy at this center. For RaySearch, this agreement further strengthens our prominent role in both treatment planning and oncology information systems for proton therapy centers in Europe.
    Johan Löf, founder and CEO, RaySearch
    MedAustron is a true pioneer in the field of ion therapy, and it has been a pleasure and honor to have them as a close partner for more than a decade. I am pleased that our successful collaboration now deepens and that RaySearch can continue supporting MedAustron in their ambitions, in Austria as well as in their international expansion plans.
    Johan Löf, founder and CEO, RaySearch
    We are pleased that we have signed a collaboration agreement with RaySearch as one of the leading institutions in advanced cancer treatment solutions. In this partnership, we will benefit of research activities for our treatment center and also for new product installations of the MedAustron Multi-Ion 800 product from our own products & services division. Our experience and know-how as the first world-wide customer for the entire RayWorld software suite will help both companies in their strategic international growth plans.
    Ludwig Gold, Managing Director, MedAustron
    We're excited to return to ASTRO in San Diego, meeting valued partners as well as customers and potential customers. We are also eager to showcase our latest product innovations to attendees joining us in our booth.
    Johan Löf, founder and CEO, RaySearch
    In the second quarter of 2023, net sales rose by 49 percent. Revenue from support rose by 39 percent. Operating profit amounted to SEK 18.2 M (-19.5) in the second quarter and to SEK 41.9 M (10.0) for the first half-year.
    Johan Löf, CEO of RaySearch
    Participating at AAPM has always been of great value for RaySerach and I am looking forward to fruitful discussions with both customers and partners in research.  Considering that Houston is also the home of one of our main customers and collaboration partners adds to the importance.
    Johan Löf, founder and CEO, RaySearch
    It is satisfying to see the increased interest for RayCare as well as more clinics using the products in their clinical routine. We continue to further develop the product at a high pace and this release marks an even more integrated solution with the rest of our products to provide an efficient and superior user experience.
    Johan Löf, founder and CEO, RaySearch
    With RayStation 2023B we show our strong dedication in providing world-class solutions for treatment planning. Adaptive replanning and high-level of integration of different systems at the clinic will pave the way towards personalized treatments and improved patient care.
    Johan Löf, founder and CEO, RaySearch
    RaySearch is the market leader in proton therapy planning, worldwide.  The fact that proton delivery systems have become affordable to physician owned organizations is an exciting development, driven by the availability of single room solutions and increased clinical evidence supporting the use of protons.  Supporting this widespread use, RayStation has the most advanced functionality of any product in the world, yet it remains accessible at every level.  We look forward to supporting the South Florida Proton Center.
    Johan Löf, founder and CEO, RaySearch
    I am very pleased to hear that the first treatment with CyberKnife using RayStation and RayCare has been successfully carried out at this world-class center. I am impressed by the ambitious program at CHUV and we are happy to support them with a complete software suite that enables optimization of operational efficiency and improved treatment quality.
    Johan Löf, founder and CEO, RaySearch
    I am pleased that our long and successful collaboration with UMCG is now being extended to preclinical research. Together with the team at PARTREC, UMCG's new research facility, we look forward to continued research and development at the forefront.
    Johan Löf, founder and CEO, RaySearch
    Henrik Bergentoft has done a good job during his short time at RaySearch and we wish him the best of luck in his continued career. With Annika Blondeau Henriksson assuming the role of interim CFO with immediate effect, we will have a competent professional ensuring our financial department’s capacity while the recruitment of a successor is underway.
    Johan Löf, founder and CEO, RaySearch
    The strong demand for RayStation from proton therapy clinics continues and I am pleased that we can support Sumitomo’s compact system, making this technology available in an optimal way to cancer patients in the region. RaySearch has always had the ambition to support all available machines on the market.
    Johan Löf, founder and CEO, RaySearch
    The sale is due to private financial reasons. I remain committed to the company with continued strong confidence in RaySearch's future. We are well positioned for continued growth and I look forward to continuing to lead and develop RaySearch towards our strategic goals.
    Johan Löf, founder and CEO, RaySearch
    We are very pleased that ABCPTR has selected RayCare from RaySearch. By supporting yet another treatment machine, this also confirms our already strong position in the particle therapy industry.
    Johan Löf, founder and CEO, RaySearch
    This order from Shinva is indicative of the strong position that Shinva has in the Chinese market. We appreciate the partnership with Shinva and that they, and their customers in China, choose RayPlan as their treatment planning system. The Chinese market has great potential for the future, and we look forward to a continued strong collaboration with Shinva.
    Johan Löf, founder and CEO, RaySearch
    We are thrilled to join forces with B dot Medical in this groundbreaking collaboration. By combining our respective expertise, we can drive innovation and contribute to the advancement of proton therapy technology. Together, we are committed to improving cancer treatment outcomes and making proton therapy more accessible to patients globally.
    Johan Löf, founder and CEO, RaySearch
    As previously communicated, achieving interoperability between RayCare and TrueBeam has taken longer than originally planned. That said, we have learned a lot in the process, and we appreciate the dedication of the Varian engineering teams in this work. We expect that this will drastically increase the addressable market for RayCare, and we look forward to exploring additional potential areas of collaboration and interoperability with Varian products.
    Johan Löf, founder and CEO, RaySearch
    In the first quarter of 2023 revenue increased 10.6 percent. Support revenue rose 13.2 percent. Operating profit amounted to SEK 24 M (30).
    Johan Löf, CEO of RaySearch
    We look forward to deepening our strategic partnership with BEBIG Medical. The collaboration will enable closer connectivity between our respective products and enhance the quality and availability of cancer treatment for patients worldwide.
    Johan Löf, founder and CEO, RaySearch
    Being at ESTRO and to be able to interact with many customers in a short time frame is always one of the highlights during the year. This year I am particularly happy to present several important collaborations with our partners. At RaySearch we believe that open interfaces and joint collaborations are important step towards further advancements in the field of radiation therapy.
    Johan Löf, founder and CEO, RaySearch
    We are pleased to help NYU Langone – Long Island to enhance treatment quality and efficiency by implementing RayStation for all their treatment techniques and machines.
    Johan Löf, founder and CEO of RaySearch
    We are pleased that Yonsei has started clinical treatments with carbon ion therapy using RayStation and RayCare. RaySearch is proud to take part in the field of carbon ion therapy as a leading supplier. We are also pleased to see that our RayCare oncology information system with Yonsei now is in clinical use in Asia.
    Johan Löf, founder and CEO, RaySearch
    It is gratifying that we start the year with growth in net sales and an improvement in profitability compared to the full year 2022. It is regrettable that we are not meeting our covenants, but the company has a stable financial situation with liquid funds at a reassuring level.
    Johan Löf, founder and CEO, RaySearch
    This is an important milestone for RaySearch. We have put a lot of effort into developing the by far most advanced treatment planning system for ion treatments, including support for all available machines. Today, we see that our efforts have paid off and that we with more than 100 clinics have about 80 per cent of the global market.
    Johan Löf, founder and CEO, RaySearch
    In the fourth quarter of 2022, order intake increased by 49 percent and net sales rose 40 percent. Operating profit amounted to SEK 21 M (-17).
    Johan Löf, CEO of RaySearch
    Japan is an important market for RaySearch and the fact that an impressive number of Japanese radiotherapy centers have chosen RayStation as one of their tools in the fight against cancer shows that there is great confidence in our products. We are committed to continue developing innovative software for ever better and more advanced cancer treatments.
    Johan Löf, founder and CEO, RaySearch
    RaySearch is a leader in treatment planning for proton therapy and we are proud that yet another prominent proton clinic has selected RayStation. We look forward to supporting OSUCC – James in their clinical operation.
    Johan Löf, founder and CEO, RaySearch
    We are proud to supply both RayStation and RayCare to this extensive investment in proton therapy in Spain. For RaySearch, this means a further strengthening of our leading position in treatment planning for protons as well as a significant increase of our customer base for RayCare. The fact that all centers will use both RaySearch products will bring many synergies, both in terms of implementation and clinical practice of radiation therapy in Spain.
    Johan Löf, founder and CEO, RaySearch
    In the third quarter of 2022, order intake increased by 71 percent and net sales rose 55 percent. Operating profit amounted to SEK 12 M (-27) in the third quarter and SEK 22 M (-37) for the first nine months.
    Johan Löf, CEO of RaySearch
    It is satisfying to note that the quarter had the highest order intake and net sales ever for a third quarter. It is regrettable that we are moving our reporting date, however I am confident and assured that we have taken the necessary steps to ensure future reporting.
    Johan Löf, founder and CEO, RaySearch
    “We look forward to collaborating with the McLaren Proton Center on both conventional proton therapy and exciting new treatment approaches.  RaySearch recently announced a partnership with Leo Cancer Care, and the implementation of RayStation in the McLaren center will enable the center to fully utilize this technology.
    Johan Löf, founder and CEO of RaySearch
    We are excited to being back on site at ASTRO to meet partners and existing and new customers to showcase the latest innovations with our products. Among other things, we are proud to highlight promising innovations within online adaptive together with our partner Accuray, as well as presenting our new partnerships with Leo Cancer Care and GE HealthCare.
    Johan Löf, founder and CEO, RaySearch
    Pick a time period -
    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top